

## **Product datasheet for TL312173V**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## IL20 Receptor alpha (IL20RA) Human shRNA Lentiviral Particle (Locus ID 53832)

**Product data:** 

**Product Type:** shRNA Lentiviral Particles

Product Name: IL20 Receptor alpha (IL20RA) Human shRNA Lentiviral Particle (Locus ID 53832)

**Locus ID:** 53832

Synonyms: CRF2-8; IL-20R-alpha; IL-20R1; IL-20RA

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** IL20RA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001278722, NM 001278723, NM 001278724, NM 014432, NM 014432.1, NM 014432.2,

NM 014432.3, NM 001278724.1, NM 001278723.1, NM 001278722.1, BC113574, BC113602,

BM713319

UniProt ID: Q9UHF4

**Summary:** This gene encodes a member of the type II cytokine receptor family. The encoded protein is a

subunit of the receptor for interleukin 20, a cytokine that may be involved in epidermal function. The interleukin 20 receptor is a heterodimeric complex consisting of the encoded protein and interleukin 20 receptor beta. This gene and interleukin 20 receptor beta are highly expressed in skin, and are upregulated in psoriasis. Alternative splicing results in

multiple transcript variants. [provided by RefSeq, Jul 2013]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).